These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 12877089)

  • 1. [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
    Satoh J
    Nihon Rinsho; 2003 Jul; 61(7):1224-9. PubMed ID: 12877089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
    Yu JG; Javorschi S; Hevener AL; Kruszynska YT; Norman RA; Sinha M; Olefsky JM
    Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
    Phillips SA; Ciaraldi TP; Kong AP; Bandukwala R; Aroda V; Carter L; Baxi S; Mudaliar SR; Henry RR
    Diabetes; 2003 Mar; 52(3):667-74. PubMed ID: 12606507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
    Sugiyama Y; Murase K; Ikeda H
    Nihon Rinsho; 2000 Feb; 58(2):370-5. PubMed ID: 10707560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
    Sugiyama Y
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():416-21. PubMed ID: 12387027
    [No Abstract]   [Full Text] [Related]  

  • 6. Thiazolidinediones--tools for the research of metabolic syndrome X.
    Komers R; Vrána A
    Physiol Res; 1998; 47(4):215-25. PubMed ID: 9803467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
    Dubois M; Vantyghem MC; Schoonjans K; Pattou F
    Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):511-23. PubMed ID: 12527853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
    Henry RR
    Clin Ther; 2003; 25 Suppl B():B47-63. PubMed ID: 14553866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic and additional vascular effects of thiazolidinediones.
    Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
    Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.
    Seufert J; Lübben G; Dietrich K; Bates PC
    Clin Ther; 2004 Jun; 26(6):805-18. PubMed ID: 15262452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.
    Strowig SM; Raskin P
    Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of a thiazolidinedione compound as a new antidiabetic drug].
    Toyota T
    Nihon Rinsho; 2001 Nov; 59(11):2211-8. PubMed ID: 11712410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diabetes mellitus].
    Kawano M; Kanazawa Y
    Nihon Rinsho; 2000 Feb; 58(2):421-5. PubMed ID: 10707569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A futile metabolic cycle activated in adipocytes by antidiabetic agents.
    Guan HP; Li Y; Jensen MV; Newgard CB; Steppan CM; Lazar MA
    Nat Med; 2002 Oct; 8(10):1122-8. PubMed ID: 12357248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adiponectin, obesity, and cardiovascular disease.
    Fasshauer M; Paschke R; Stumvoll M
    Biochimie; 2004 Nov; 86(11):779-84. PubMed ID: 15589686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.
    Derosa G; Salvadeo SA; D'Angelo A; Fogari E; Ragonesi PD; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
    Arch Med Res; 2008 May; 39(4):412-9. PubMed ID: 18375253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.
    Combs TP; Wagner JA; Berger J; Doebber T; Wang WJ; Zhang BB; Tanen M; Berg AH; O'Rahilly S; Savage DB; Chatterjee K; Weiss S; Larson PJ; Gottesdiener KM; Gertz BJ; Charron MJ; Scherer PE; Moller DE
    Endocrinology; 2002 Mar; 143(3):998-1007. PubMed ID: 11861525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
    Vázquez M; Silvestre JS; Prous JR
    Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):515-23. PubMed ID: 12500431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.